Giuseppe Curigliano, MD, PhD

Articles

Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

September 9th 2021

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.

Future Opportunities With Novel Therapies for HER2+ Breast Cancer

September 8th 2021

Novel therapies that show promise in addressing treatment gaps in HER2-positive breast cancer, and exciting data that are expected to be reported on at the upcoming ESMO 2021 meeting.

R/R Metastatic HER2+ Breast Cancer Treatment Considerations

September 8th 2021

Factors that impact treatment selection for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy.

HER2+ Breast Cancer: Key Takeaways From HER2CLIMB

September 8th 2021

An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.

Standard of Care for R/R Metastatic HER2+ Breast Cancer

September 8th 2021

Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.

Dr. Curigliano Discusses Immunotherapy Trials in Breast Cancer

May 31st 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

March 19th 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.